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ENHANCING ADHERENCE TO PRESCRIBED OPIOIDS USING A MOBILE-BASE 
APPLICATION: A PILOT STUDY OF FEASIBILITY IN CHRONIC NON-CANCER PAIN. 
 
By Daniel Mouaffo Sop  
 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University.  
 
Virginia Commonwealth University, 2017.  
 
Major Director: Ding-Yu Fei, PhD, Department of Biomedical Engineering 
  
Nonadherence (overutilization and underutilization) to prescribed opioids underlies the current 
us opioid epidemic/crisis. Methods to measure opioid adherence have limitations or are only 
proxy measures. Examples of such methods include: patient recall, pill counts, refill rates, 
biological monitoring such as urine toxicology, and electronic monitoring such as mems caps.  
While not perfect, software programs or apps which collect instantaneous patient reports of 
utilization using reminders, and those that have the potential to encourage appropriate 
behavior, are gaining popularity as a way to monitor adherence.  We were interested to 
develop such a software app to monitor opioid adherence. In this study we present feasibility of 
a mobile monitoring and reporting system that would provide an accurate unbiased screening 
tool to systematically analyze opioid adherence. In addition, the software simultaneously 
measures pain. 
We developed this mobile-based application, OpPill, for the iOS and Android smartphone 
platforms. Development and testing consisted of using existing deep mixed methods research 
on pain behavior and opioid use among sickle cell disease (SCD) patients (n=21) to determine 
the most effective application content and/or structure. The application was used by sickle cell 
disease patients (n=30) at the Virginia Commonwealth University Health System (VCUHS). 
  
 
xii 
The Mobile Applications Rating Scale: a new and validated tool for assessing the quality of 
health mobile apps for engagement, functionality, aesthetics, information quality, subjective 
quality, relevance and overall impact was administered post usage to evaluate the application.   
 
A total of 28 patients were recruited to review and test the software at one sitting. Patients 
were equally divided among males and females, had a high school to graduate level 
education, with a majority having some college education. The majority of the population found 
the application to be relevant for their care.  When surveyed to select all the items they thought 
the application was designed to do, 37% indicated that it was aimed at improving their physical 
health, and 37% thought it was designed to help them set goals, while 29.6% and 22.2% said 
respectively that it helped them feel happy/healthy and reduce negative emotions. In regards 
to the targeted population, patients where asked if the content was appropriate for sickle cell 
and the majority said it was well-targeted, with negligible issues (88.8%). Study participants 
were asked if they would recommend this application to people with sickle cell disease and 
100% said they would recommend the application. Patients were also asked to report on the 
completeness of information within the app, the majority (96%) reported on the application’s 
completeness while 4% estimated the information to be minimal or overwhelming. The quality 
of information as it pertains to sickle cell patients was overwhelimingly reported to be relevant 
(91.7%); only 8.3% found the application to be poorly relevant to sickle cell disease. The 
application’s performance was positively rated at 100% while the ease of its use positively 
rated at 91.7%. Most participants (85.7%) found the application to be interesting to use while 
74% found it entertaining. All users found the application’s navigation to be logical and 
accurate with consistent and intuitive gestural design.  
When asked how many times patients thought they would use the application in the next 12 
months, results showed 24% would use it over 50 times, 36% would use it somewhere 
  
 
xiii 
between 10-50 times and 40% would only use it 3-10 times. Some patients reported that they 
would pay for the application (24%) while 44% said they might pay and 32% reported that they 
would not pay for this application. On a scale of 1 to 5 with 1 being the lowest and 5 being the 
highest, mean engagement, functionality, aesthetics and information scores were calculated 
and yielded the following results: mean engagement score: 3.96, mean functionality score: 
4.54, mean aesthetics score: 3.96 and mean information score: 3.91.     
 
We conclude that surveyed patients believe it is feasible to use a smartphone application 
specifically targeted to monitor opioid use and behavior in patients with sickle cell disease 
(SCD)-associated pain. Results are limited in that these feasibility results are based on a one-
time survey of patients shown the software app at one sitting, and not on repeated app use 
over time. Future work should include validation via quantifying repeated app use over time, as 
well as reported behaviors such as opioid use while using the software app. 
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Chapter 1 
 
 
Introduction  
American health literacy is poor.  In 2004, the Institute of Medicine’s report on health 
literacy estimated that more than 90 million people have difficulty understanding, using 
and acting on health information (David Kindig MD, 2004)1 
Prescriptions and prescription errors are common.  According to the Patient-Centered 
Primary Care Collaborative, more than 3.5 billion prescriptions are written annually in 
the United States, and four out of five patients who visit a physician leave with at least 
one prescription. Medications are involved in 80 percent of all treatments and impact 
every aspect of a patient’s life2.  The Institute of Medicine conducted five separate 
studies that placed the rate of medication errors per 100 doses from 2.4 percent to 11.1 
percent in inpatient hospital settings3.  
Patient safety and important health outcomes are compromised by poor health literacy, 
leading to poor adherence, medication errors by patients, and medication misuse. 
According to the International Society for Pharmacoeconomics and Outcome Research 
(ISPOR), adherence is “the extent to which a patient acts in accordance with the 
prescribed interval, and dose of a dosing regimen”4. Poor adherence causes 
approximately 33% to 69% of medication-related hospitalizations and accounts for 
$100 billion in annual healthcare costs.5 Irrespective of disease, medication complexity, 
or how adherence is measured, the average adherence rate to chronic medication 
therapy is approximately 50%.6.  Medication nonadherence can affect patient health 
adversely, negatively impact a patient’s relationship with his/her care provider, skew 
results of clinical therapy trials, and increase health resource consumption.7,8  
Mobile health (mHealth), the general term for the use of mobile phones and other 
wireless technology in medical care (http://www.himss.org/mhealth), is being sought to 
improve prescribing, adherence, patient safety, and health outcomes. Research 
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conducted in 2016 by Park Associates found that more than 10 percent of the nation’s 
caregivers are also using mHealth tools to track medications for their charges. That 
same study found that almost 30 percent of caregivers would be interested in using 
those tools, as would 41 percent of Americans who expect to care for a loved one in the 
future9.  
Perhaps nowhere is medication nonadherence more in the news than in opioid 
nonadherence, specifically opioid misuse. Currently opioids are prescribed using 
conventional intervals, for example, every 4 hours as needed for pain in the case of a 
short-acting opioid, and every 12 hours in the case of a long-acting opioid10.  Patients 
may deviate from their prescribed specific dosing instructions. 
It is well-recognized there is an opioid prescription epidemic in the US. Accordingly, the 
CDC has issued guidelines that recommend against the use of high dose opioids11.  In 
addition, efforts are underway to promote safe opioid use, to improve opioid adherence, 
and to prevent prescription opioid diversion by identifying high-risk patients and by 
educating patients as well as families regarding the safe use, storage, and disposal of 
opioids.  
A significant portion of Patients with sickle cell disease (SCD), the most common 
inherited blood disorder, use prescribed opioids regularly. SCD affects the hemoglobin 
structure of red blood cells such that they form a sickle shape. SCD produces a 
progressively disabling illness with severe clinical consequences. Symptoms of SCD 
vary but are highlighted by sudden acute unbearable pain throughout the body, known 
as crises in addition to profound, hemolytic anemia. A large descriptive diary study of 
pain and opioid use in SCD found that opioid use was prevalent including short acting 
and long acting. The unbearable and unpredictable pain puts patients with SCD at risk 
of being deprived of effective pain management because of the more recent heightened 
scrutiny on prescription opioid use.  In a study aiming to understand adherence to 
opioids in sickle cell disease, results showed that many patients with SCD take their 
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medication differently than instructed on the prescription during and between painful 
episodes, both underusing and overusing their opioids, when compared to the 
clinician’s instructions12. Because of the high prevalence of opioid use in patients with 
SCD, they are often stigmatized as drug-seeking13.  Thus, when using the ISPOR 
definition, many SCD patients exhibit medication nonadherence. 
Even though SCD is a unique condition as it relates to pain, in many ways it typifies 
chronic non-cancer pain. Clinicians who prescribe opioids to patients with chronic non-
cancer pain must be concerned about the opioid epidemic and about patient safety, 
while simultaneously addressing patients’ pain needs.   
Currently popular methods to measure adherence, including patient self-reports, pill 
counts, refill rates, biological monitoring, and electronic monitoring, have limitations and 
are only proxy measures.14,15,16 Patient self-reports rely on memory and are prone to 
inaccuracies and recall bias.17 Pill counts are unreliable if patients fail to return bottles 
or discard pills before the count. Research in Sickle cell disease has shown that 
biological monitoring such as urine toxicology screens are not very precise at 
quantifying medication use.18   
The use of electronic monitoring devices that detect the opening and closing of a 
medication bottle, such as the Medication Event Monitoring System (MEMS), has 
shown validity in providing an adequate representation of the complexities of patient 
adherence in a trial of patients undergoing remission with ulcerative colitis19.  However, 
these devices do not reflect direct medication ingestion, and could be thwarted by 
patients attempting to hide overuse or underuse.  
Currently, the most reliable way to quantify medication adherence are digital pill or 
ingestible biosensor systems. These systems rely on a radiofrequency emitter which 
directly measures medication ingestion.  A study utilizing a digital pill to Assess Real-
Time Medication Adherence20 found the system also was an adequate representationof 
patient adherence.  But although reliable, this system is impractical for use in SCD.  
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These systems are currently poorly available, still largely experimental, and too 
expensive for wide-spread use21, especially for SCD care, due to the financial 
disparities of these patients.  
In order to safely start, adjust, taper, and stop opioids, clinicians need to better 
understand contextual opioid adherence—just how and under what circumstances their 
patients use their prescribed opioids.  Ideally, clinicians need to know when a patient 
takes the opioid, what dose is taken at the time, and the biopsychosocial and 
environmental context around that particular opioid dose.  Context should include. the 
level of pain that triggered the opioid use, the weather at the time, and momentary 
stress surrounding the dose. All are known to affect pain in SCD.22,23  With a better 
understanding of the opioid use pattern and context, clinicians can better identify pain 
triggers or exacerbating factors unique to each patient, develop a better individualized 
opioid management plan, and more intelligently apply non-pharmacologic interventions 
to mitigate pain and opioid use.   
To supply this information, mHealth, specifically smartphone applications, offers a 
potentially useful technology. mHealth Apps are already widely used for health 
improvement in other chronic diseases.  For example, current data demonstrate that 
electronic mobile devices using reminder systems through traditional means of 
telecommunication, like Short Message Service (SMS) text messaging, improve 
adherence and behavior and can be useful in measuring adherence24. One study found 
that teenagers with asthma who used a specialized system to create and schedule 
personal text message reminders gave the system high ratings for acceptability, ease 
of use, and usefulness; however, asthma control was not impacted25. Further, in a 
study to help control blood glucose levels in patients with diabetes using a 
comprehensive, Web-based education system and cellular phone access, the 
frequency of accessing the eMOD (electronic Management of Diabetes) software was 
significantly correlated to the change in glycosylated hemoglobin levels26. 
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mHealth can offer numerous special techniques for helping patients take their 
medications given their customizable content, affordability and portability. Furthermore, 
with a medicinal services industry seeing non-adherence rates of as high as 50 percent 
and yearly expenses of between $100 billion and $300 billion, the potential return on 
investment from utilizing cell phone adherence applications could potentially outweigh 
the burden of non-adherence. This accessible innovation offers numerous highlights 
that can enable patients and healthcare providers in improving medication taking 
behavior.  
Thus, the goal of our project was to develop and test the acceptability and usability of a 
mobile software application among adult patients with Sickle cell disease (SCD) to 
increase adherence to prescribed Opioids. Additionally, the application would allow 
them to report context-specific data surrounding their medication intake behavior, self-
reported pain and Vaso-Occlusive crises. 
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Chapter 2 
 
Literature Review  
I. Sickle Cell Disease and Pain  
 
(Samir K. Ballas, 2012) 27Many individuals with SCD experience daily pain, which 
affects all aspects of life. There is great variability in the rate of recurrence and severity 
of pain in a SCD patient’s experience. Acute and/or chronic pain may be hard to 
tolerate and mentally exhausting. Furthermore, this pain may limit the quality of life of 
patients’ daily activities. Additionally, the constant pain is significantly associated with 
depression, anxiety, cognitive development, weight loss, disturbance in sleep, mood 
swings and distorted communication, and possibly loss of employment and productivity. 
Moreover, mistrust from other patients, caregivers, family members, and friends may 
lead to negative psychological effects28. 
II. Opioid analgesics in pain management for sickle cell pain 
 
(I Boyd, 2014)29Prescription opioids minimize the chronic disease pain by providing 
pain control to SCD patients. Thus, opioid analgesics are the most commonly accepted 
method of pain management for sickle cell. Chronic and acute opioid treatment have 
been accepted as a suitable and effective method in pain management.  Many studies, 
theories, and anecdotes demonstrate clinically significant pain relief from stable doses 
of opioid medication. Reduced length of hospital stay and reduced resource use of 
health care systems result from effective pain management and mobility. At-home pain 
relief using “as-needed” (PRN) analgesics for severe sickle cell pain is common; 
however, long-acting “scheduled” medication is more effective and could provide more 
consistent pain relief, generate less euphoria upon administration, allow slower 
development of tolerance, and offer more favorable side-effect profiles than short-
acting counterparts. Many of these individuals with SCD manage pain at home using 
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prescribed opioid analgesics, which have been found to give significant pain relief when 
used appropriately30. 
III. Opioid use in sickle cell disease is controversial 
 
(T.R. Kotila, 2015)31Opioid use in sickle cell disease (SCD) is controversial. SCD 
patients may distrust physicians and exhibit pseudo-addiction behaviors, including 
hoarding and going to several physicians to acquire more medication. As with other 
patients using prescribed opioids, SCD patients may become addicted or manifest 
criminal behavior with opioid use, although this is a rare occurrence. A few studies 
regarding long-term opioid use in SCD patients have been published32, but an in-depth 
analysis of how and why SCD patients use prescribed opioids on a daily and 
continuous basis has not been done.  
These prescription opioids are often under-prescribed due to physicians’ reluctance to 
prescribe adequate dosages of opioid analgesia and concerns about addiction, 
tolerance, and side effects33 .Physicians tend to overestimate the prevalence of opioid 
dependence in patients with sickle cell crises despite a low 3% incidence of opioid 
analgesic addiction and may even harbor negative attitudes towards SCD patients in 
general34. Nevertheless, the recent rise in prescription opioid use for cancer and non-
cancer pain management remains controversial due to widely divergent perspectives 
and evidence regarding inadequate and unnecessary treatment of pain. Over the last 
two decades, the proportion of office visits in which prescriptions for potent opioids 
were given increased from 2% to 9%35. Despite this rise in rate of opioid prescription 
and use, there is still a significant data showing inadequate pain management36. 
To address this gap in the pain management literature for SCD and perhaps relevant to 
opioid use in non-cancer, chronic pain disorders, there is a need to explore how and 
why patients use their prescribed opioids. 
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IV. Momentarily Biopsychosocial-Spiritual (BPSS) Reasons 
 
(Lou Ella V. Taylor, 2014)37Research on opioid use has not yet focused on time- or 
context-specific use of opioids and motivation to deviate from prescribed opioid 
regimens. In part, this is due to the irreducible nature of pain. Several models have 
been created to describe the nature of pain; one of the most prominent models is the 
Biopsychosocial Model, which divides pain into biological, psychological, and social 
components. Some researchers consider spirituality another component of pain 
management due to the nature of religious and spiritual coping methods many chronic 
pain sufferers utilize. The Biopsychosocial-Spiritual (BPSS) model when describing 
reasons behind different methods of opioid medication use in sickle cell disease 
because chronic pain in adults with sickle cell disease (SCD) is a complex 
multidimensional experience that includes biological, psychological, sociological, and 
spiritual factors. 
V. Why adherence to prescribed opioid in SCD? 
 
(Alsalman AJ 1, 2013)38Despite wide-spread acceptance in the use of opioids for 
chronic, non-cancer pain, there is a concern for the possibility of abuse, misuse, and 
diversion.  In order to resolve this controversy, we must explore the motivation for 
patients to experience adequate pain control versus any adverse effects and the 
potential for abuse. It is important to evaluate medication-taking behaviors, including 
adherence to an established regimen, normal non-adherence to that daily regimen, and 
any aberrant behavior.  
However, use of opiates is controversial due to its side effects and risk of addiction. 
Distrust from physicians and peers may lead some SCD patients to improperly use 
opioids and exhibit pseudo-addiction behaviors, leading to discord between healthcare 
providers and SCD patients. This indicates the need for effective pain management, in 
particular, research analyzing the motivations behind opioid use. 
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Despite the pain and medication adherence models in the literature, current models fail 
to capture time- or context-specific use of opioids. The unpredictable and severe nature 
of SCD pain crises as well as the conventional use of short-acting (and sometimes 
long-acting) opioids in the SCD patient population presents as an ideal disease 
paradigm in which patterns of opioid usage and adherence may be studied. Also, 
despite nearly a century of common use of opioids to treat pain, there is surprisingly 
scarce research on improving adherence to prescribed opioid in non-cancer pain and 
the relationship between this pain and opioids intake. Additionally, patterns underlying 
opioid use under specific contexts (environmental, emotional) such as those in most 
BPSS phenomena have not yet been tested. Alsalman AJ (1, 2013) used a confidential 
mixed-methods study where short surveys were utilized to quantitatively examine 
patterns of adherence (or nonadherence) motivations with qualitative exploration of 
these reasons for a more comprehensive analysis.  
VI. Smartphones, Applications and Medicine  
 
(Lindsey Dayer, 2013)39With the increased adoption of smartphones, there has been a 
simultaneous explosion of health focused mobile applications.  A report from the IMS 
Institute for Healthcare Informatics counted over 165,000 healthcare apps available for 
download, many of which can be used to improve adherence for patients taking daily 
medications. 
Medication nonadherence is a significant barrier to disease management, with 
estimates of nonadherence ranging from 25% to 50% depending on factors such as 
disease, insurance coverage, and patient characteristics.  Medication nonadherence 
also affects health outcomes and healthcare costs. The US spends $100-$300 billion 
annually on avoidable health care costs due to nonadherence40.  In response to the 
costs and poor health outcomes, various tailored interventions have been developed 
and tested to improve poor medication adherence including electronic pill boxes, text 
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messaging, online interventions (such as assessments), and counseling. However, 
despite these efforts, we still need additional tailored and effective tools to improve 
adherence41. 
The prevalence of smartphone usage has dramatically increased over the past several 
years.  Presently, 77% of US adults own a smartphone, which is a big jump from the 
35% who owned a smartphone in 2011.  With smartphone use on the rise, Dayer and 
colleagues published a 2013 article about the potential benefits of mobile apps: 
they are relatively inexpensive, easily accessible, and available 24/7. These software 
interface can provide tailored reminders (both for dosages and refills), and can function 
as a repository for medication and user-specific information.42 
Medication management and adherence doesn’t just affect patients and their 
doctors. Research conducted in 2016 by Park Associates found that more than 10 
percent of the nation’s caregivers are also using mHealth tool to track medications for 
billing purposes. That same study found that almost 30 percent of caregivers would be 
interested in using those tools, as would 41 percent of Americans who expect to care 
for a loved one in the future43. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
    
 
11 
 
Chapter 3 
 
 
Methods  
I. A rationale  
 
Although reliable and top of the line systems such as MEMScaps and Biosensor 
ingestible pills exist and can provide close to or real-time adherence information, their 
implementation for sickle cell disease care as a method for measuring adherence is 
virtually impossible for several reasons. The first and main reason being the disparities 
that surround Sickle Cell disease and the population it affects. For example, the funding 
disparities for research on sickle cell compared to other pediatric diseases are very 
large. Cystic fibrosis, a disease that affects primarily Caucasians, occurs in only a third 
of the numbers affected by SCD, but received 3.5 times more NIH funding. Private 
funding from foundations was about 400 times higher for cystic fibrosis44.The disparities 
associated to Sickle cell Disease are not limited to SCD care, research or funding. The 
debilitating aspect of the disease and the unpredictability of onset for associated vaso-
occlusive crisis severely limits SCD patients’ ability to secure and maintain gainful 
employment thus causing reliance on government subsidized programs, decreased 
quality of care and decreased quality of life45 . These programs such as Medicare, 
Medicaid and other disability programs have reimbursement and category limits which 
would exclude Ingestible Biosensor and MEMScap implementation. The above noted 
adherence monitoring systems burden of costs would become patients’ responsibility, a 
responsibility that could not be met due to their inability to secure and maintain gainful 
employment. Furthermore, there are challenges associated with the use and 
implementation of MEMScaps and ingestible sensors. In a study aiming to understand 
the challenges of using MEMScap, results show that acceptance of this technology 
proved difficult, as many patients either declined upfront or dropped out because they 
did not want to use the MEMS. Outcome of the final survey indicated, 41% found 
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transferring medication into the MEMS bottle difficult and 27.2% reported that the 
MEMS was a burden and/or difficult to transport. Another 22% of the patients reported 
that using the MEMS changed their routine, and 10.2% worried about missing their 
medications46. Ingestible biosensor also known as the digital pill is a newly FDA 
approved technology that records when a dose has been taken via electronic signals 
sent to a wearable patch (and then, to a smartphone), via a safe-for-consumption 
sensor inside the pill. Although the generated data is objective, this technology would 
incur high costs that SCD patients may not afford and raises several new questions and 
concerns such as privacy and HIPPA related concerns. Ingestible technology will put 
meaningful statistics and metrics in front of patients and doctors, in real time, from 
anywhere in the world. Arlyn Scales also highlights the fact that we don't know exactly 
what would happen if it malfunctioned, and the only way to find out is to use the 
technology. It's tricky, however, because the stakes are higher for a medical tool than if 
an iPhone dies or malfunctions47. Data from previous studies demonstrate that 
electronic mobile devices using reminder systems through traditional means of 
telecommunication, like Short Message Service (SMS) text messaging, improve 
medication adherence and patient behavior and can be useful in measuring adherence 
in the short term48. Investigators determined that sending photographs of medication 
capsules through cellular phones before ingestion provided more accurate time 
measures of adherence49. One study found that teenagers with asthma who used a 
specialized system to create and schedule personal text message reminders gave the 
system high ratings for acceptability, ease of use, and usefulness; however, their 
asthma control was similar to baseline50. In a study using a comprehensive, Web-
based education system cellular phone access to help control blood glucose levels in 
patients with diabetes, the frequency of accessing the eMOD (electronic Management 
of Diabetes) system through a cellular phone was directly related to the change in 
glycosylated hemoglobin levels51. Although a systematic review of Internet-based 
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adherence interventions found promising results, it also found that the 13 studies 
lacked quality measurements of adherence52. Various studies of the use of 
smartphones in the clinical setting have been performed53, but studies empirically 
testing smartphone apps acceptability in chronic pain with aims to improve adherence 
are lacking. Thus, the rationale behind our study design.  
II. Specific Aims 
 
- To develop an Electronic Data Capture platform using the OpPill mobile 
application to capture context-specific data associated with prescription opioid 
use.   
- To test the acceptability and usability of the OpPill mobile application among 
adult patients with Sickle cell disease (SCD) to report context-specific data.   
III. Study Design  
 
The OpPill mobile application (app) was designed and built to contain the following 
design features: (1) An opioid use diary to allow the user to report (a) the type of opioid 
used, (b) the dose taken, (c) the time the medication was taken, and (d) context specific 
information associated with the opioid use (2) A pain diary to allow the user to report (a) 
pain intensity levels, (b) the time pain intensity is being experienced and (c) context 
specific information associated with the pain intensity level.  (3) The ability for 
researchers to monitor and track pain level, opioid use, and context-specific information 
overtime.  (4) The ability for the research team to communicate and provide feedback 
to the user. (5) The ability for the application to alert the research team of various 
conditions such as (a) the user’s failure to access the application within a specified 
period of time, and (b) if opioid use exceeds a specified dose amount over a specified 
period of time.  
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1) Phase 1: Focus Groups 
 
Phase 1 conducted by another researcher involved the recruitment of 21 patients for 
individual interviews to gain knowledge about sickle cell patients’ typical contexts and 
activities reported associated with their pain and opioid use. The results of this work 
(Abdulkhaliq J. Alsalman, 2013) reported the following: population studied consisted of 
52% (n=11) men and 48% (n=10) women with a mean age of 36 years, ranging from a 
diverse background of socioeconomic and educational levels. Medical history and 
psychological variables were assessed at baseline time. Relevant medical history 
predictors included history of pain days and history of analgesics medications54. This 
multi-phase mixed method study described the opioid taking behavior and the reasons 
for adherence to prescribed opioid of 21 SCD patients in the Adult Sickle Cell Anemia 
Clinic at Virginia Commonwealth University Health System (VCUHS) in Richmond, 
Virginia. Adherence was described and assessed by the investigator following an 
extensive semi-structured interview and preliminary survey regarding adherence 
behavior. The investigator used 24 questions in an open-ended, face-to-face interview 
and preliminary survey to collect data about adherence to the prescribed opioid 
regimens. Qualitative thematic analysis uncovered several patterns of opioid-taking 
behavior and several related biopsychosocial-spiritual phenomena. These patterns and 
phenomena portrayed a new six-domain conceptual framework that addresses the 
complex individual, relational, environmental, cultural, and systemic issues surrounding 
opioid taking-behavior in SCD. From this six-domain framework, the investigator 
organized the explanatory factors into a new method of classification, which included 
two overarching domains: intra-patient (biological, psychological, spiritual), extra-patient 
(social support, provider relationships, institutional norms, culture, legal and 
governmental policy). This classification provided a roadmap for future research that 
led to phase 2 of our project. The six domains explored in the research offered 
guidance towards understanding a complex explanation of the effect of pain, its 
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pharmacotherapy, and medication taking behaviors on an individual’s health that 
simultaneously bridges all healthcare domains. The context themes and activity themes 
that emerged were programmed as pre-populated lists into the application.   
2) Phase 2: Prototype Development 
 
Phase 2 of the research study involved actual software application development. The 
OpPill application was developed to be accessible using an IOS or android powered 
device. The application was built using client-server architecture. The client component 
was built in native SWIFT code and the server component using Google Cloud Next 
Enterprise server to broker data exchange. The system contains a password-protected 
Web-interface allowing safeguards to protect users while enabling researchers the 
ability to create studies, add new study participants, and access results. Data entered 
by participants regardless of the device used will be transmitted to the server using an 
encrypted (HTTPS) protocol over a Secure Socket Layer (SSL) connection. The server 
was hosted on the Google Cloud behind a firewall in a network secure environment. A 
username and password was required to access data on the user end and the 
researcher’s end. Following the development of the OpPill prototype, feedback was 
obtained, and a subsequent final model was built based on the feedback provided. 
Suggested recommendations were addressed before proceeding to high-fidelity testing.  
3) Phase 3: Low-Fidelity Testing 
 
Following the development, the app was trialed with SCD adults to determine the 
application content and/or structure’s accuracy and appeal. The application was also 
demonstrated to experienced SCD clinicians for content validity evaluation and clinical 
significance. Input received from patients and clinicians was included in the final 
phases of the application’s development.  
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4) Phase 4: High-fidelity Testing   
 
Phase 4 involved applying the application developed to additional evaluation for its 
Usability, Clinical Feasibility and Compliance (High fidelity User-Centered Design 
parameter). This was done through an approved Institutional Review Board application 
to assess the application’s quality at the Sickle Cell Clinic within the VCU Ambulatory 
care center using a Cross-sectional cohort design. We recruited a purposive, 
heterogeneous sample of 30 adult SCD patients for this study. 
Patients were asked to use the application during their clinic visit recording their own 
pain, opioid use, and circumstances surrounding their input while accessing the 
application for engagement, functionality, aesthetics, information quality, and subjective 
quality. At the end of each user’s trial, The Mobile Application Rating Scale (MARS), a 
newly validated tool was used to assess patient’s feedback regarding the app (See 
Appendix); notably: Engagement, Functionality, Aesthetics, Information accuracy, 
Subjective Quality, and Perceived Impact. Responses were evaluated to explore 
emerging themes and field notes on 1) ease of app use, 2) general endorsement of the 
app (i.e. The features of the app whether it is appealing to adults with SCD or not), 3) 
rewarding and trust building aspects of the app, and 4) recommendations for improving 
the user-interface of the app. The MARS tool was first published in 2015 explaining the 
process used for its development and validation, thus its rarity. The MARS tool 
development involved a comprehensive literature search to identify articles containing 
explicit Web- or app-related quality rating criteria. English-language papers from 
January 2000 through January 2013 were retrieved from PsycINFO, ProQuest, 
EBSCOhost, IEEE Xplore, Web of Science, and ScienceDirect. The search terms were, 
“mobile” AND “app*” OR “web*” PAIRED WITH “quality” OR “criteria” OR “assess*” OR 
“evaluat*55”.  Per Stoyanov, criteria for the assessment of app quality were categorized 
by an expert panel to develop the new Mobile App Rating Scale subscales, items, 
descriptors, and anchors. Derivation of the MARS tool involved selecting 10 apps from 
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a sample of 60 apps that were randomly selected using an online randomizer. The 10 
Applications were used to pilot the MARS rating procedure and the remaining 50 
Applications provided data on irater reliability.  
IV. Assurance of Access to Patient Sample 
 
For pilot studies, a sample size in the range of 10 to 20 subjects is sufficient for 
feasibility assessments. 21 patients participated in phase1 and 30 patients in phase 4. 
Adults SCD subjects came from a mixture of the (Pain In Sickle Cell Epidemiologic 
Study) PiSCES and (Start Healing In Patients with HydroxyUrea) SHIP-HU cohort but 
were enriched by new adult SCD patients. Patients in this cohort met conceptually 
either the American Pain Society definition or the International Association for the Study 
of Pain’s definition of chronic pain. 
V. Data Collection 
 
We collected participants demographics and Pain Characteristics to include age, race, 
gender, education (highest completed) and self-reported income (in categories). 
Opioids adherence and disease characteristics were also collected in the form of 
phenotypic manifestation of pain and patient’s disease genotype. Acceptability, 
Usability and efficacy of the OpPill was tested using the validated Mobile Application 
Rating Scale (MARS) tool. The MARS tool was designed by a research team involved 
in the development and validation of eHealth and mHealth interventions, or ‘eTools’55. 
The scale aimed to provide researchers, clinicians and developers with a list of 
evaluation criteria, and a gradient response scale for their objective evaluation. There 
are three main MARS factors: 1, the MARS mean; this is the mean of four objective 
subscales (Engagement, Functionality, Aesthetics, and Information). 2, Subjective 
Quality. 3, Perceived Impact. Subjective Quality and Perceived Impact are based on 
the rater's’ own impression of the eTool, including its usability and perceived 
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effectiveness. Additionally, alternative pain quenching practices along with body 
temperature at the time of collection was captured. 
VI. Data and Safety Monitoring 
 
The research involved no more than minimal risk to the subjects. All patient data were 
de-identified. Patient medical records were used partly to pre-screen patients for 
eligibility. As part of conditions for treatment, patients sign authorization for this use. All 
de-identified information was maintained in a HIPAA-compliant manner. 
VII.Institutional Data and Safety Monitoring Board 
 
The VCU IRB served as the institutional review board for this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
    
 
19 
 
Chapter 4 
 
 
Analysis  
 
Characteristics and demographics of patient participants were determined using simple 
descriptive statics, as was the mobile application rating scale. The application’s quality 
criteria were clustered within the engagement, functionality, aesthetics, information 
quality, and subjective quality categories. The subjective qualities were customized to 
be sickle cell disease specific in order to relate to the patient population that was 
evaluating the OpPill application. Each MARS item used a 5-point scale (1-Inadequate, 
2-Poor, 3-Acceptable, 4-Good, 5-Excellent), descriptors for these rating anchors were 
written for each item. In cases where an item may not be applicable for all apps, an 
option of not applicable was included.  
Following the MARS tool guidelines, scores were obtained by individually computing 
the mean scores for engagement, functionality, aesthetics, and information quality. 
Additionally, an overall mean app quality total was calculated. Mean scores instead of 
total scores are used because an item can be rated as not applicable. Additionally, 
mean scores are used to provide quality ratings corresponding to the familiar format of 
star ratings. The subjective quality sickle cell specific items were analyzed separately 
by computing the mean and applying the CORR procedure to evaluate the correlation 
of demographics, engagement, function, aesthetics and information with SCD 
outcomes of the OpPill application.  The MARS app classification section was analyzed 
using simple statistics for descriptive purposes only. 
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Chapter 5 
 
Results  
I. Patient Population: Focus group and Low Fidelity testing – Phase 1  
 
Study participation consisted of a one-time, approximately 1.5 hour in-person interview 
using interview guide (see Figure 1). The interviews were audio-recorded and 
subsequently transcribed for qualitative analysis. Among other inclusion and exclusion 
criteria, eligible subjects were to be between the ages 18 and 65 years, Having SCD 
diagnosis, African-American patients and feeling pain for > 30% of days in the last 
month. All recruited subjects have received opioid outpatient prescriptions within the 
previous 12 months. 
Qualitative thematic analysis revealed three phenomena:  1) SCD patients exhibited 
various opioid-taking behavior patterns including adherence, overuse, underuse, and 
erratic use; 2) Several biopsychosocial factors hindered or motivated opioid use: severe 
pain intensity, side effects, stress, family gatherings, unplanned meetings, religious 
attendance, and anticipatory fear adverse outcomes; 3) Behaviors varied based on the 
time of day, week, month, or year, and also based on the momentary contexts at times 
of actual and projected doses. Approximately 57% (n=12) of the participants were 
women. Patients ranged in age from 18 to 58 years. Of the 21 patients, 5 (24%) 
participants were married. More than half (57%) of the participants have the SS 
genotype of SCD. While approximately one-third (33%) of the participants have the SC 
genotype of SCD. When asked about rating their pain intensity on the average in last 
30 days, the mean reported pain intensity was 5.5 (SD=1.7). A higher proportion (62%) 
of the study reported more than >50% of pain days in the last 30 days. More than half 
(52% (n=11)) of the participants were on both long-acting and short-acting prescribed. 
Notably a higher proportion (62%) of the participants have either college or some 
college education. Approximately 57% of the sample reported their income to be in the 
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range of $0 to $25,000. Approximately 24% of the patient samples are smokers. 
Similarly, around 24% of sample reported drinking alcohol. The interview was added 
below in appendix 1 and demographics representing the patient population is 
summarized in table 1 below. 
 
Table1: Phase 1 demographics and Other Characteristics for Respondents 
Variables Frequency (%) 
 n = 21 
Age Mean (SD) 35.4 (11.4) years 
Gender   
Female 57% 
Marital Status   
   Married 24% 
Education   
High school or less 38% 
College or some college 62% 
Family income   
   $ 0 to $25,000 56% 
$25,001 to $50,000 19% 
$50,001 and Over 25% 
Pain Days   
≥ 30-50 days 38% 
>50 days 62% 
Average Pain intensity (1-10) 
Mean (SD) 5.5 (1.7) 
Prescribed Opioid Regimen  
Short-acting (PRN) Only 52% 
Both short- and long-acting 48% 
Drink Alcohol  
   Yes 24% 
Smoke Cigarette  
   Yes 24% 
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Figure 1: Developing the interview guide 
 
 
 
 
II. OpPill Application Development Phase 2 
 
The application was designed to reflect the needs and allow for input related to 
recurring topics gathered from phase 1. The Application was designed to be 
implemented for android and apple smartphone devices. The application was built 
using rapid prototyping techniques. The application’s screenshots for both the prototype 
and final product are presented in figure 2 and 3 below. A wireframe of the final product 
is shown below in figure 4.  
 
 
 
 
 
 
    
    
 
23 
 
Figure 2: Prototype Screenshots 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Final Application Screenshots  
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Figure 4: OpPill application Wireframe 
 
 
 
III. Phase 3: Low Fidelity Testing  
Following the development, the app was trialed with adults SCD caregivers to include 
clinicians, social workers, patient navigators, and pharmacy personnel for feedback 
regarding the application’s appearance, content validity and flow of information. 
Suggestions were made to improve the application’s fluidity, to break down the 
anatomical body image into body sections for clarity, to make the application more 
engaging, to improve the application’s responsiveness, to improve dull coloring, to add 
provider information collection functions and personal medications information 
collection functions. The above noted feedback was verbally collected in an open 
conversation manner and no formal structure. These recommendations were taken into 
consideration and implemented in last iteration of the application’s development.  
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IV. Study Participants Phase 4  
 
 
Patients’ ages ranged from 18.77 to 58.83, with a mean of 36.56 years. Overrall 46.4 
%( 13) participants were males whereas 53.6 %( 15) were females. 2 patients were 
withdrawn the sample due to acute onset of Vaso-Occlusive crisis. A ranking of 
participant’s education showed that 25%(7) had completed an education equivalent to 
that of a high school graduate or a GED equivalent, 39.3%(11) had completed some 
college, 14.3%(4) had completed a degree equivalent to that of a 2year college, 
7.1%(2) had completed a 4-year degree and 14.3%(4) had completed a master’s 
degree. None of the participants had completed a doctoral or professional education. 
Income representation was spread from <$10,000 (25%), $10,000 to $19,000(29.2%), 
$20,000 to $29,000(12.5%), $40,000to $49,000(12.5%), $50,000 to $59,000 (4.2%) to 
≥$60,000 (4.2%). Sickle cell patient’s genotypes represented in the study were as 
follows: Hemoglobin SS 26.9%(7), Hemoglobin SC 42.3%(11), Hemoglobin S β0 
Thalassemia 11.5%(3), Hemoglobin S β+ Thalassemia 3.8%(2) and 15.4% where not 
sure of their genotypes at time of the study.  
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Table 2: Phase 4 study population demographics 
                                      Population Demographics   
Gender  N Frequency (%) 
Male 13 46.4 
Female 15 53.6 
Education N Frequency (%) 
<HS 0 0 
HS/GED 7 25 
Some College 11 39.3 
2-yr College 4 14.3 
4-yr College 2 7.1 
Master's 4 14.3 
Doctoral 0 0 
Professional 0 0 
Income N Frequency (%) 
<10,000 6 25 
10,000-19,000 7 29.2 
20,000-29,000 3 12.5 
30,000-39,000 0 0 
40,000-49,000 3 12.5 
50,000-59,000 1 4.2 
≥60,000 4 16.7 
Genotype N Frequency (%) 
Hemoglobin SS 7 26.9 
Hemoglobin SC 11 42.3 
Hemoglobin S β0 Thalassemia 3 11.5 
Hemoglobin S β++ Thalassemia 1 3.8 
Don't Know 0 0 
Not Sure 4 15.4 
Other 0 0 
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IV. Application Classification  
 
After allowing patients to use the application post consenting, two focus questions were 
asked to gauge their understanding of what the application was design to do and 
reason why the study was being conducted. This was kept in the MARS tool to gather 
information regarding topics that would gain the most traction in the design aspect of 
the application and the mean of delivery or approach with any future application as it 
pertains to the reason for conducting the research. Please note that participants could 
select more than one answer for each question. Results indicated the majority believed 
the application to have been designed to help them set goals (37%), to improve their 
physical health (37%), to help them feel happy and healthy (37%) and to reduce 
negative emotions (22.2%). These are the general themes that fall under the rationale 
driving this project indicating that our participants had a general understanding of what 
the application what being built for. We expected there to be a relatively high percent of 
patients selecting behavior change as one of the reasons for building the application, 
however the observed results were a mere 3.7%. The complete distribution for this 
question was summarized in graph 1 below. 
We also gauge participants understanding of the reason why the research study was 
being conducted to evaluate their understanding of the study for which they had just 
consented to participate in. The vast majority (77.8%) reported that this study was 
conducted to obtain feedback regarding the application which satisfied our 
expectations. The next ranking response was education/information which can be 
explained given that we are aiming to empower patients by getting them involved in 
their care. The complete distribution was summarized in graph 2 below.  
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Graph 1: Focus – Understanding the design of the app 
 
 
 
Graph 2: Focus – Understanding the reasoning behind the research study 
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V. MARS tool Scores  
 
The app quality criteria were clustered within the engagement, functionality, 
aesthetics, information quality, and subjective quality categories, to develop 23 
subcategories from which the 23 individual MARS items were developed. Each 
MARS item used a 5-point scale (1-Inadequate, 2-Poor, 3-Acceptable, 4-Good, 5-
Excellent), descriptors for these rating anchors were written for each item and 
results summarized in table 3 and table 4. A copy of the Mars tool was provided in 
appendix 3. 
  
Table 3: MARS tool category scores  
Variables  N Mean Min  Max  Std Dev  CI -  CI + 
Engagement  27 3.93 3 5 0.73 3.64 4.22 
Functionality 24 4.54 3 5 0.66 4.26 4.82 
Aesthetics  25 3.92 3 5 0.81 3.59 4.25 
Information  22 3.91 2 5 0.87 3.53 4.29 
 
 
Graph 3: MARS Score Chart  
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1) Engagement 
 
Engagement was gauged by assessing the application’s ability to be fun, interesting, 
customizable, interactive (e.g. sends alerts, messages, reminders, feedback, enables 
sharing), and well-targeted to audience. Although not vigorously found to be 
entertaining the overwhelming majority found the application to be well targeted, 
interactive and customizable. Results are summarized and represented in table 4 and 
graph 4. 
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Table 4 – Application Engagement scores 
 
SECTION A 
Engagement – fun, interesting, customizable, 
interactive (e.g. sends alerts, messages, reminders, 
feedback, enables sharing), well-targeted to audience 
  
Entertainment:  Is the app fun/entertaining to 
use N Frequency 
Dull, not at all 5 18.5 
Mostly Boring 2 7.4 
OK, for brief time 11 40.7 
Moderately  6 22.2 
Highly  3 11.1 
Interest: Is the app interesting to use?  N Frequency 
Dull, not at all 2 7.1 
Mostly Boring 2 7.1 
OK, for brief time 4 14.3 
Moderately  9 32.1 
Highly  11 39.3 
Customization:  Does it provide/retain all 
necessary settings/preferences for apps 
features (e.g. sound, content, notifications, 
etc.)? Counts Percent 
Doesn't Allow 0 0 
Insufficient 2 7.7 
Basic 8 30.8 
Numerous Options 7 29.6 
Complete Tailoring 9 34.6 
Interactivity: Does this app allow user input, 
provide feedback, contain prompts (reminders, 
sharing options, notifications, etc.)?  N Frequency 
None 0 0 
Insufficient 0 0 
Basic 7 28 
Variety 10 40 
Very High 8 32 
Target group: Is the app content (visual 
information, language, design) appropriate for 
sickle cell patients? N Frequency 
Completely inappropriate  0 0 
Most inappropriate  0 0 
Acceptable  3 11.1 
Well-targeted 12 44.4 
Perfectly targeted 12 44.4 
A.  Engagement mean score =  3.93  
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Table 5: Section A – Mean Engagement Score  
 
 
 
Graph 4: plot- MARS mean engagement score 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2) FUNCTIONALITY 
 
The application’s functionally was assessed by asking patients to report on the app 
functioning, ease to learn, navigation, flow logic, and gestural design of app. On this 
topic results indicated that majority of patients found the application to be easy to use 
and learn, to perform as intended and easy to navigate. Results summarizing patients’ 
report on application functionality were summarized and graphed in table 5 and graph 
5. 
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Table 6: Application functionality scores 
SECTION B 
 
Functionality – app functioning, easy to learn, 
navigation, flow logic, and gestural design of 
app   
Performance:  How accurately/fast do the app 
features (functions) and components  
(buttons/menus) work? N Frequency 
Broken 0 0 
Some functions work  0 0 
Works Overall 5 20.8 
Mostly Functional 7 29.2 
Perfect/timely response 12 50 
Ease of use: How easy is it to learn how to use 
the app; how clear are the menu labels/icons 
and instructions? N Frequency 
No/limited Instructions 0 0 
Useable after a lot of time/effort 1 4.2 
Useable after some time/effort 1 4.2 
Clear Instructions 9 37.5 
Simple 13 54.2 
Navigation: Is moving between screens 
logical/accurate/appropriate/ uninterrupted; are 
all necessary screen links present? N Frequency 
Difficult 0 0 
Useable after a lot of time/effort 0 0 
Useable after some time/effort 2 8.3 
Easy to use 5 20.8 
Perfectly clear 17 70.8 
Gestural design: Are interactions 
(taps/swipes/pinches/scrolls) consistent and 
intuitive across all components/screens? N Frequency 
Completely Inconsistent 0 0 
Often Inconsistent 0 0 
OK w/ some inconsistencies 3 12.5 
Mostly consistent 9 37.5 
Perfectly consistent 12 50 
B. Functionality mean score =    4.54  
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Table 7: Section B – Mean Functionality Score 
 
 
Graph 5: plot- MARS mean functionality score 
 
 
 
 
 
 
 
 
 
 
3) Aesthetics  
 
Application aesthetics were assessed by asking patients to rate questions regarding the 
app’s graphic design, overall visual appeal, color scheme, and stylistic consistency. 
Although 2 people indicated that the application did not look good and one patient 
reported that the application had a bad design, the majority found the application’s 
layout to be satisfactory, clear or professional. Most people found the application’s 
graphics to be of good quality and to have high visual appeal. Results were 
summarized in tabled 6 and graph 6.  
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Table 8: Application Aesthetics Scores 
SECTION C 
 
Aesthetics – graphic design, overall visual appeal, color 
scheme, and stylistic consistency   
Layout: Is arrangement and size of 
buttons/icons/menus/content on the screen 
appropriate or zoom able if needed? N Frequency 
Very bad design 0 0 
Bad Design 1 4 
Satisfactory 3 12 
Mostly Clear 12 48 
Professional 9 36 
Graphics: How high is the quality/resolution of 
graphics used for 
buttons/icons/menus/content? N Frequency 
Very poor 0 0 
Low quality 8 8.3 
Moderate Quality 5 20.8 
High Quality 10 41.7 
Very High Quality  7 29.2 
Visual appeal: How good does the app look? N Frequency 
None 1 4 
Little 1 4 
Some 9 36 
High 8 32 
Very High 6 24 
C. Aesthetics mean score =     3.92  
 
 
Table 9: Section C – mean Aesthetics Score 
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Graph 6: plot- MARS mean aesthetics score 
 
 
 
 
 
 
 
 
 
4) Information Quality  
 
The application’s quality of information was rated by participants through questions 
asking them to rate the content for accuracy, quality, quantity, goals and understanding. 
Mean scores were calculated and indicated that the majority found the information to be 
of high quality. Results were summarized and graphed in table 7 and graph 7.  
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Table 10: Application information quality scores 
SECTION D 
 
Information – Contains high quality information 
(e.g. text, feedback, measures, references) 
from a credible source. Select N/A if the app 
component is irrelevant.   
Accuracy of app description (in app store): 
Does app contain what is described? N Frequency 
Misleading 0 0 
Inaccurate 0 0 
OK 3 12.5 
Accurate 14 58.3 
Highly Accurate 7 29.2 
Goals: Does app have specific, measurable and 
achievable goals (specified in app store 
description or within the app itself)? N Frequency 
N/A 2 8.3 
App has no chance 0 0 
Very little chance 3 12.5 
OK 8 33.3 
Likely 7 29.2 
Highly likely 4 16.7 
Quality of information: Is app content correct, 
well written, and relevant to Sickle Cell disease 
? N Frequency 
N/A 1 4.2 
Irrelevant 0 0 
Barely relevant 1 4.2 
Moderately relevant 5 20.8 
Relevant 7 29.2 
Highly relevant 10 41.7 
Quantity of information: Is the amount of 
information in the App complete? N Frequency 
N/A 0 0 
Minimal 1 4 
Insufficient 0 0 
OK 7 28 
Broad Range 10 40 
Comprehensive 7 28 
Visual information: Can you understand the 
images displayed within the App? N Frequency 
N/A 0 0 
Complelely unclear 0 0 
Mostly unclear 0 0 
OK 3 12 
Mostly clear 7 28 
Perfectly clear 15 60 
D. Information mean score =  3.91  
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 Table 11: Section D – Mean Information Score 
 
 
Graph 7: plot- MARS mean information score 
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5) Sickle Cell Specific and Awareness – The CORR procedure  
In an effort to better understand the feedback provided by the patients, we applied the 
CORR procedure to evaluate the relationship between demographic information, sickle 
cell specific responses and the MARS classifications (engagement, functions, 
aesthetics and information quality) as it relates to the application.    
The CORR procedure computes Pearson correlation coefficients, three nonparametric 
measures of association, and the probabilities associated with these statistics. Prior to 
analysis, a Simple statistic table is generated alongside with a variable table (see table 
8) to account for variables that will be used during the analysis. See table 8 for simple 
statistics reports. Pearson correlation statistics are computed from observations with 
non-missing values for each pair of analysis variables. When using the Pearson 
correlation coefficient, the correlation coefficient can range in value from −1 to +1. The 
larger the absolute value of the coefficient, the stronger the relationship between the 
variables. An absolute value of 1 indicates a perfect linear relationship. A correlation 
close to 0 indicates no linear relationship between the variables. Table 10 displays a 
summary of the analysis.  
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Table 12: The CORR Procedure variable table 
 
 
 
Table 13: The CORR Procedure Simple Statistics  
 
 
 
Table 14: Spearman Correlation Coefficients – The CORR Procedure 
 
 
6 With Variables:
7 Variables:
The CORR Procedure
recommend_to_scd awareness_1 knowledge_2 attitudes_3 intention_to_change help_seeking
engagement function aesthetics information age educ_ordinal income_ordinal
Variable N Mean Std Dev Median Minimum Maximum
recommend_to_scd 25 4.44000 0.86987 5.00000 3.00000 5.00000
awareness_1 24 3.87500 1.48361 5.00000 1.00000 5.00000
knowledge_2 24 3.83333 1.52277 5.00000 1.00000 5.00000
attitudes_3 23 3.86957 1.17954 4.00000 1.00000 5.00000
intention_to_change 24 4.00000 1.10335 4.00000 1.00000 5.00000
help_seeking 24 4.12500 1.03472 4.00000 1.00000 5.00000
engagement 28 3.74940 0.89198 3.80000 1.00000 5.00000
function 24 4.42708 0.60108 4.62500 3.00000 5.00000
aesthetics 25 3.90000 0.76073 4.00000 2.50000 5.00000
information 25 3.96000 0.74833 4.00000 2.40000 5.00000
age 28 36.56849 12.17949 36.25479 18.77534 58.83562
educ_ordinal 28 3.46429 1.34666 3.00000 2.00000 6.00000
income_ordinal 24 3.25000 2.23120 2.00000 1.00000 7.00000
Simple Statistics
engagement function aesthetics information age educ_ordinal income_ordinal
recommend_to_scd
0.54582
0.0048
25
0.71018
0.0001
24
0.58993
0.0019
25
0.61963
0.0010
25
_0.01079
0.9592
25
0.03013
0.8863
25
0.01074
0.9632
21
awareness_1
0.60610
0.0017
24
0.26131
0.2284
23
0.52606
0.0083
24
0.50695
0.0115
24
0.06086
0.7776
24
_0.05341
0.8042
24
_0.12140
0.6102
20
knowledge_2
0.56786
0.0038
24
0.18557
0.3966
23
0.44796
0.0281
24
0.45136
0.0268
24
0.14122
0.5104
24
_0.03578
0.8682
24
_0.16201
0.4950
20
attitudes_3
0.69285
0.0002
23
0.31349
0.1554
22
0.49637
0.0160
23
0.50843
0.0132
23
_0.14116
0.5206
23
_0.04050
0.8544
23
_0.13037
0.5838
20
intention_to_change
0.49635
0.0136
24
0.31724
0.1402
23
0.52093
0.0091
24
0.58114
0.0029
24
0.06158
0.7750
24
0.08693
0.6863
24
_0.17931
0.4494
20
help_seeking
0.36803
0.0768
24
0.20212
0.3550
23
0.36442
0.0800
24
0.37597
0.0702
24
_0.01397
0.9483
24
_0.07404
0.7310
24
_0.24146
0.3051
20
Spearman Correlation Coefficients
Prob > |r| under H0: Rho=0
Number of Observations
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Pearson correlation calculation showed several positive and linear correlation between 
objective scales (Engagement, Information quality, Functionality, and Aesthetics) and 
Sickle cell specific questions. Engagement positively and linearly correlated with the 
willingness to share the application with others (R=054582, P>0.05, p=0.0048), Ability 
for the application to raise awareness about Sickle Cell Disease (R=0.60610, P>0.05, 
p=0.0017) , The ability for the application to increase Sickle Cell Knowledge amongst 
users (R=0.56786, P>0.05, p=0.0038) , the ability for the application to increase 
attitude towards sickle cell disease care  (R=0.69285, P>0.05, p=0.0002), The 
application’s ability to increase motivation to change sickle cell disease care 
(R=0.49635, P>0.05, p=0.0136) . Positive linear correlations were also found between 
Aesthetics and the application’s ability to raise awareness about sickle cell disease 
(R=0.52606, P>0.05, p=0.0083), the application’s ability to increase SCD knowledge 
(R=0.44796, P>0.05, p=0.0281), the application’s ability to increase attitude to sickle 
cell disease care (R=0.49637, P>0.05, p=0.0160) , the ability for the application to 
increase motivation to change sickle cell disease care (R=0.52093, P>0.05, p=0.0091). 
Positive linear correlations were also observed between the information quality 
subscale and the application’s ability to raise awareness (R=0.50695, P>0.05, 
p=0.0115), increase sickle cell knowledge (R=0.45136, P>0.05, p=0.0268) , increase 
attitude towards SCD care (R=0.50843, P>0.05, p=0.0132) , the ability to motivate 
intention to change SCD care (R=0.58114, P>0.05, p=0.0029). Although there were no 
statistical significance in the correlation of the application’s functionality and most of the 
sickle cell specific questions, a strong linear correlation was found with patient’s 
willingness to recommend the application (R=0.71018, P>0.05, p=0.0001). This 
correlation was the highest and most statistically significant observation.  
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Chapter 6 
Discussion & Conclusion 
Discussion  
Although there are several studies evaluating the use of web-based applications in 
medicine, there is currently no published literature evaluating the acceptance and 
feasibility of web-based application for adherence to prescribed opioids in SCD. 
Therefore, we offer alternative explanations and comparisons of the current results with 
past research on cancer and non-cancer pain conditions. 
In addition, SCD patient care has a greater focus on not just minimizing pain to the 
level of “enough,” but to allow SCD patients to interact in society and the workplace 
with independence despite the chronic condition. Many participants emphasized (and 
advised other patients of) their need to perform (limited) activity and maintain a well-
being to minimize the effects of SCD on their lives. Additionally, care for SCD patients 
may best be optimized with better medication prescribing behavior, better healthcare 
delivery, and better overall support. These factors are often questioned and distrusted 
by healthcare teams due to the disparity existing in sickle cell care. The goal of this 
study was to develop and test the feasibility of a mobile application for adherence to 
prescribed opioids and capture context-specific data associated with prescription opioid 
use. This goal was selected with the aim of indirectly bridging the gap of trust between 
sickle cell patient and provider. Patients with sickle cell disease are often categorized 
as “drug-seekers” because of the high dosage of opioids they need in order to appease 
their pain. The recent laws, regulations and attention to opioids prescriptions and 
opioids behaviors exacerbated this issue amongst provider thus their reluctance to 
prescribe high dose of opioids. Building a web-based application that allowed for 
patients to input their pain behavior is one way that the VCUhealth system was able to 
improve care for sickle cell patients. This software allowed patients to document, their 
opioids intake behavior and their pain rating and evaluating if the software as a means 
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of communication was accepted and welcomed in the sickle cell community as a way of 
building trust and establishing report with the care team. The majority of users in our 
study possessed an Android device (64%) vs iPhones (36%).  
The MARS tool, a reliable, multidimensional measure for trialing, classifying, and rating 
the quality of mobile health apps was used to evaluate the quality of our application. 
The evaluation was divided into categories including: Engagement, Functionality, 
Aesthetics, and Information Quality. Each section was scored according to the MARS 
tool scoring guide by calculating each one of the above-named scales means and the 
overall mean app quality total score. The application’s functionality rated highest 
(M=4.54, SD= 0.66) followed by engagement (M=3.93, SD=0.73), aesthetics (M=3.92, 
SD=0.81), and information quality (M=3.91, SD=0.87). The overall mean app quality 
total score was M=3.98, SD=0.77. These means are reported on a scale of 1 to 5 with 1 
being the poorest quality and 5 being the greatest quality.  
These results trendily mirrored those reported in a review and content analysis of 
engagement, functionality, aesthetics, information quality, and change techniques in the 
most popular commercial apps for weight management using the MARS tool. Bardus et 
al reported using the tool to independently assess 23 popular app’s features, quality 
and content. Their reported results were: Engagement (M=3.0, SD=0.9), Functionality 
(M=3.8, SD=0.9), Aesthetics (M=3.4, SD=1.2) and information Quality (M=2.2, SD=0.7) 
with a total score (M=3.1, SD=0.8)56. An emerging trend with functionality leading in 
rating scores is observed between our study and their review although our overall 
performance per category is superior.   These results indicate a high internal 
consistency and speak to the quality of the application that was developed. The 
application acceptance was analyzed by using the COOR procedure to find relationship 
between the objective subscales (Engagement, functionality, Aesthetics and 
Information quality) and subjective sickle cell specific questions.  The app quality 
indicated by MARS scores was positively correlated with number of subjective sickle 
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cell specific topics. The Highest positive linear correlation was found between the 
application’s functions and the willingness for participants to recommend the application 
to other sickle cell patients (R=0.71018, P>0.05, p=0.0001). There were no 
relationships found between age, income and education and any of the sickle cell 
specific subjective measures indicating no bias due to age, income or level of education 
in the application’s rating using the MARS tool. Although no studies are without 
limitations, these results highlight the feasibility of a mobile software application as a 
mean of measure of adherence and context specific information surrounding Sickle Cell 
patients medication intake behavior and their self-reported pain.  
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Conclusion  
The current technology driven world ruled by apps, interconnectivity and 
communications begs for the need of more disease-oriented web-based applications. 
Although large number of medication reminder apps are available in the app stores, the 
majority of them aim to cover a broad spectrum of disease and lack the specific focus 
on one disease which often only gives a snapshot or birds eye view into a patient’ 
medication intake behavior. The goal of this project was to develop and test the 
acceptability of an application developed for a specific group or type of patients to help 
improve adherence to their opioids intake. Results showed that the application worked 
well and was well received in the targeted population. Engagement scores were also 
elevated indicating that patients increasingly want to become more engaged in their 
own health care, and with patient specific applications such as the we designed and 
used for this project, we give our patients the ability to positively impact their behaviors, 
improve their adherence, bridge the gap of trust between patient and provider and 
impact their overall health. These findings however could be biased according to the 
Hawthorne effect. The Hawthorne effect refers to the inclination of some people to work 
harder and perform better when they are being observed as part of an experiment. 
When transposed in a clinical research environment, this indicates that positive results 
could be due to the simple fact that participants are aware that they are being 
observed. The Hawthorne effect was evaluated in a randomized controlled trial were 
researchers aimed to compare minimal follow-up to intensive follow-up in participants in 
a placebo controlled trial of Ginkgo biloba for treating mild-moderate dementia and 
found that more intensive follow-up of individuals resulted in a better outcome than 
minimal follow-up, as measured by their cognitive functioning57. The bias generated by 
the Hawthorne effect pushes us to consider longitudinal evaluation with minimal 
intervention in future work when evaluating medial health applications. Our Study 
focused on evaluating the application’s quality, future work should consider adding a 
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verification mechanism to validate the self-reported entries.  Potential verification 
mechanisms could be items such as the newly FDA approved digital pill — a 
medication embedded within and ingestible sensor that could provide objective 
verification of medication adherence.  
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Appendix  
Appendix 1: Interview Guide 
 
Semi-Structure Interview Guide 
 
Project Title: Understanding Adherence to Prescribed Opioids in Sickle Cell Disease 
Arrival  
Welcoming patient and having some informal chat in order to put them in their ease and make 
them feel comfortable. Opening Questions: How are you today? How is [school] [Work]? 
“Please tell us your first and last name.” 
The following statement is to be read to the participants before each interview.   
“Thank you so much for agreeing to participate in this study.  What we would like to do today is 
talk about issues connected with sickle cell disease pain. We will be discussing how you manage 
your pain, drawing on your experiences.   We want to learn from you to help other people in the 
future. We have a number of areas we would like to cover, including how patients use their 
medicine and other ways of pain control. At any time if you think of any comments or 
experiences, we would very much like to hear them, even if that’s not what we are talking about 
right then.  We want to understand the different ways people cope with their pain.” 
Introduction 
Medication adherence: “As I mentioned before, the first thing we will ask you is a series of 
questions about your experience with pain and how it made you feel.   Then we will ask you a 
series of questions about how patients take their prescribed pain medicines. I am interested in 
things that people do that affect their ways of taking their pain medicines. The purpose of the 
study is not to judge whether your ways of taking pain medicine are good or bad. The purposes 
of the study are to just learn exactly how pain affects you and what you do about it.  That 
includes what medicines you take, and how you take them, regardless of how they are 
prescribed. Please try and answer each question with as much detail as possible.”  
1) Beginning the interview: I'd like to start out this interview by hearing a little bit about your 
experiences with Sickle Cell Disease.  Can you tell me how you usually experience your 
disease?  
Probe: 
a) How has your sickle cell disease pain affected your personal life? Think about when you 
are in pain–during that time, how are your family, life style, daily activities affected? 
2) Please tell me all the medical problems that cause you pain.  
Explore:  
a) Follow-up questions (f/u): Of all the problems you have that are causing you pain, which 
one is the worst? 
3) What medicines are you currently taking for your pain?  (Please tell me all you can 
remember, regular or occasional, prescription or over the counter). 
Explore:  
a. (f/u): How well do these medicines work for you? 
 
In the following questions, I would like to know about how you use your strong pain 
medicine like Morphine, MS Contin, Tramadol, Tylenol III, Codeine, Darvocet, 
propoxyphene, Percocet, OxyContin, oxycodone, Vicodin, Lortab, hydrocodone, Dilaudid, 
Sickle Cell Anemia and Pain (generally) 
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hydromorphone, or Pain patches (Fentantl), prescribed by a doctors. But from now on I will 
just say pain medicine for strong pain medicine. Let’s talk now about that.  
 
Adherence to Prescribed Opioid: To Identify Actual Behavior of Use 
4) It sounds like you are taking (select appropriate phrase according to above) [both] [short-
acting] [and] [long-acting] to manage your pain.  Thinking back over the last 30 days, how 
did you use your pain medicine?  
Probes: 
a. Do you usually use as needed and/or scheduled pain medicine every day? 
b. How often do you take them? How many pills do you take each time? How many 
times are you supposed to take pills each day?  
Explore: 
a. Typically, how long do you wait to take your next dose of pain medication?  
What factors influence your decision? 
b. How long does it take you to get comfortable after taking your medication? 
c. Do you ever take your medicine in a different order or dosage than prescribed by 
your doctor?  Why?  What factors influence your decision? 
d. Have you ever stopped using your medicine for any reason?  Can you tell me a 
little bit about that? 
 
 
5) The following questions below depend on answer to this question # 4) [For Adherent what 
was it that made you want to keep taking your pain medicine as prescribed?] [For Non-
adherent: Why did you decide that you wanted to quit using your pain medicine?] [For 
Erratic User: You mention that you sometimes use more and sometime use less of your pain 
medications that your doctor than prescribed of your strong pain medicines; what is the 
reason? What made you use it that way?]  
6) I know that many doctors prefer to treat sickle cell pain with a combination of as-needed and 
scheduled pain medicine or a number of different medicines at the same time. How do you 
know which kinds of medicine to use? How did you decide to take them?  
7) Besides using your pain medicine to help with pain, what other methods do you use, such as 
home remedies?  
Explore: 
a. (f/u) If you use more than one method, how do you choose which one to use when? 
How do you combine methods? 
8) Thinking about a typical day (with pain or without pain),  tell me how you usually take your 
prescriptions during that 24 hour period.    
Probes:  
a. When do you usually take your pills? 
b. Are there any times of day (or night) when you take more or less of your 
medications?Why?  
c. How would your medication usage vary on an atypical (unusual) day?  What does an 
atypical day look like for you?  Why would you change the way you use your 
medicine? 
9) Do you agree with the amount of pain medicine your doctor prescribes for your sickle cell 
pain?   
 Reasons for Underuse, Overuse, Erratic, and Quitting 
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Probes:  
a. Do you think that your doctor has you on the right medicines?  
b. What changes would you make to your drug regimen if it were up to you? 
 
10) Regimen Complexity Do you take your pain medication the way that your doctor originally 
prescribed it?  Have you ever had any problems understanding how to take your 
medications?  (If so) Tell more me about it.  
 
General Factors Affect Adherence (Motivations and Difficulties) Over the Time or 
Episodically 
Transition: Next, I would like to ask you some questions about your experiences with pain 
medicine 
11) Motivations or Factors for Use: What factor influence, encourage, or motivate you to use 
your pain medicine (scheduled pain medicine or as-needed pain medicine)? 
12) Barriers, Challenges or Difficulties of Adherence to Pain Medicine at Home: Sometimes 
SCD adults find it difficult to take medicines as the doctor has ordered. What are some 
things that make it difficult to continue taking your pain medicines as prescribed? Why?  
Explore: 
a. (f/u) Describe a time when you experienced difficulty taking your scheduled or as-
needed pain medicine.  How did these challenges affect your ways of using pain 
medicine?  
13) Family or Friends Concern of Opioid Use: Think of your environment.  By environment I 
mean the physical and social world around you. How does your environment affect the way 
you take your medicine?  
Probe:  
a. How do your family and friends affect how you take (or don’t take) your pain 
medicine? Share with us about how people in your life play a role in taking your 
medicine?  
b. (f/u) How does society affect how you take your pain medicine?  Do you feel you 
must be “responsible” to yourself or to others?  
c. How does the weather affect how you take your pain medicine? If you can, share 
with us what kinds of weather change the way you take your pain medicine. 
14) Reasons for Underuse: There are many reasons why SCD patients use less pain medicine 
than prescribed, don’t use pain medicine for a time, or choose not to use it. Thinking about 
the last three months, please tell me a story of a time when you took less of your medicine 
than you usually take or took less than you thought you needed?  
Explore: 
a. (f/u) What were the reasons for each of the times that you needed/wanted to use pain 
medicine, but didn’t use? Describe those reasons in detail.  
15) Reasons for Overuse: There are many reasons why SCD patients use more pain medicine 
than prescribed or there are times when they don’t need or want to use pain medicine, but 
they choose to use it anyway. Thinking about the last three months, please tell me a story of 
a time when you took more of your medicine than you usually take or took more than you 
thought you needed? 
Explore: 
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a. (f/u) What were the reasons for each of the times that you didn’t need/want to use 
pain medicine, but used more or used it anyway? Describe those reasons in detail. 
Using Opioid for Symptoms/Reasons Other than Pain 
16) Some SCD patients may use pain medicine for reasons other than pain. Thinking about the 
last three months, please tell me a story of a time you used your pain medicine for reasons or 
symptoms other than pain. How would you describe these reasons?  
17) Forget or Missing Doses: People have a lot of different feelings about how medicines work 
and what the results are if they miss a dose.  Thinking about the last three months, please tell 
me a story of a time you missed a dose or several doses of pain medicine.  
Explore: 
a. (f/u) How did you feel you when you missed a pill or several pills?  
b. (f/u) How important is it to you to take your medicines as prescribed? Please 
explain. 
c. (f/u) What do you do when you realize you miss/forget to take a dose of your 
prescribed medicines?  Take more, take less? Describe. 
   
Reasons for Episodic and Temporary Change in Adherence 
Using Opioid while in Pain when Feeling Worse than Usual 
18) Think back to when you were feeling worse pain than usual or when you having crises. 
What, if anything, did you do differently to get rid of your pain? 
Explore: 
a. Why do you think you chose to use your pain medicine in this way, in this situation? 
b. (f/u) What did you do when the pain was not relieved (you were still feeling pain) 
after you took your pain medicines? Did you use your pain medicine differently then? 
Did you use more or less than prescribed?  
c. (f/u) What made you decide to use the medicine in such a way?  
d. (f/u) Did the location of pain affect your way of using pain medicine? 
Using Opioid while in Pain when Feeling Good 
19) When you are feeling good, how do you use your medicine?  
20) Think back when you are/were feeling better after you took your pain medicines, how did 
you use your medicine then?  
Probes: 
a. Did you ever stop taking your scheduled or as-needed medicines when you were 
feeling good? If so, tell more about that.   
21) Describe a time for me when you were having no/little SCD pain (or you felt better) but still 
chose to take more pain medicine?   
Explore: 
a. (f/u) Why do you think you chose to use your pain medicine in this way, in the 
situation you explained to me?  
Psychosocial Factors 
Using Opioid while in Pain and Having Social Activities, Special Events, Circumstances, or 
Situation  
22) How do you use your pain medicine before, after, or during some special social event, 
activity or special situation?  
Explore: 
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a. (f/u) To what extent are you able to use your medicine as prescribed during this 
time?  Do you change your routine?  
Using Opioid while in Pain and Having Stress or Other Psychological Components 
23) How does stress in your life relate to your pain?  Which usually comes first, the stress or the 
pain?   
Explore: 
a. (f/u) How do you cope with the stress when you are in pain?  
b. (f/u) Do you change your routine (I mean the way in which you take your medicine) 
when you are in stress and in pain?  
c. (f/u) Do you change how you use your pain medicine when you are under stress? 
 
   
Ending the Interview 
24) Recommendations: Based on your experience, what information do you think is important 
for other patients and healthcare providers to know about pain medicine?  
Probes: 
a. What advice would you give a person who is considering maintaining his/ her pain 
medicine as prescribed or improving his /her way of taking pain medicine?  
To wrap up: We have come to the end of the interview. You explained before how you use 
your pain medicine and the reasons for using them. In light of what we have just been 
discussing (medicine use and reasons for use), I’d like to ask you if you have any additional, 
final comments, or anything that you think we should have talked about but didn’t? This 
concludes ends the interview. As we conclude, I would like to thank you for your assistance 
with this research project. You have been most helpful in responding to the questions. Thank 
you for taking part in this interview and for responding to the questions so thoroughly. I 
appreciate your time, interest, and openness.  How do you feel about the interview we have 
just had? May I call you if I need to clarify or add to any information you have provided?  Is 
there anything that you would like to ask me? I am happy to answer any questions that you 
may have.  
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Appendix 2: MARS Application rating scale  
 
Patient feedback survey  
Adapted from the Mobile Application Rating Scale (MARS) 
 
Patient ID:  
 
The Classification section is used to collect descriptive and technical 
information about the app.   
 
App Name:    OPpil  
 
 
Platform:                iPhone                iPad                    Android 
 
Brief description:     
 
 
 
Focus: What do you 
think that this APP is 
designed to do? 
(select all that apply) 
 
  Makes me feel happy/Healthy 
  Helps me Relax 
  Reduce negative emotions 
  Depression 
  Anxiety/Stress 
  Anger 
  Behavior Change 
  Alcohol /Substance Use 
  Helps me set goals 
  It Entertains me/Distracts me 
  Relationships 
  Physical health 
 Other      
In your opinion, why are 
we conducting this 
research study? 
(all that apply) 
 
  Assessment 
  Feedback 
  Information/Education 
  Tracking 
  Goal setting 
  Advice /Tips /Strategies /Skills 
training 
  CBT - Behavioural (positive 
events) 
  CBT – Cognitive (My 
Thoughts)               ACT - 
Acceptance commitment 
therapy   
Mindfulness/Meditation 
  Relaxation 
  Gratitude 
  Strengths based 
 Other   
 
 
 
Affiliations: To the best of your knowledge, this research is associated with 
which one of these? 
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  Unknown               Commercial                 Government                NGO              
  University 
 
Please select the 
age group in which 
you belong  
 
  Children 
(under 12)  
Adolescents (13-
17)   Young 
Adults (18-25)   
Adults 
  General 
Technical aspects of app (all 
that apply) 
 
  Allows sharing (Facebook, 
Twitter, etc.) 
  Has an app community 
  Allows password-protection 
  Requires login 
  Sends reminders 
  Needs internet  to function
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App Quality Ratings 
The Rating scale assesses app quality on four dimensions. All items are rated on a 
5-point scale from “1.Inadequate” to “5.Excellent”. Circle the 
number that most accurately represents the quality of the app 
component you are rating. Please use the choices provided for 
each response category. 
 
SECTION A 
Engagement – fun, interesting, customizable, interactive (e.g. sends 
alerts, messages, reminders, feedback, enables sharing), well-
targeted to audience 
 
1.  Entertainment:  Is the app fun/entertaining to use?  
1     Dull, not fun or entertaining at all 
2     Mostly boring 
3     OK, fun enough to entertain user for a brief time (< 5 minutes) 
4     Moderately fun and entertaining, would entertain user for some time 
(5-10 minutes total) 
5     Highly entertaining and fun, would stimulate repeat use  
 
2.  Interest: Is the app interesting to use?  
1     Not interesting at all 
2     Mostly uninteresting 
3     OK, neither interesting nor uninteresting; would engage user for a 
brief time (< 5 minutes) 
4     Moderately interesting; would engage user for some time (5-10 
minutes total) 
5     Very interesting, would engage user in repeat use  
 
3.  Customization:  Does it provide/retain all necessary 
settings/preferences for apps features (e.g. sound, content, 
notifications, etc.)? 
1     Does not allow any customization or requires setting to be input 
every time 
2     Allows insufficient customization limiting functions 
3     Allows basic customization to function adequately 
4     Allows numerous options for customization 
5     Allows complete tailoring to the individual’s 
characteristics/preferences, retains all settings  
 
4.  Interactivity: Does this app allow user input, provide feedback, 
contain prompts (reminders, sharing options, notifications, etc.)?  
1     No interactive features and/or no response to user interaction 
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2     Insufficient interactivity, or feedback, or user input options, limiting 
functions 
3     Basic interactive features to function adequately 
4     Offers a variety of interactive features/feedback/user input options 
5     Very high level of responsiveness through interactive 
features/feedback/user input options  
 
5.  Target group: Is the app content (visual information, language, 
design) appropriate for sickle cell patients? 
1     Completely inappropriate/unclear/confusing 
2     Mostly inappropriate/unclear/confusing 
3     Acceptable but not targeted. May be 
inappropriate/unclear/confusing 
4     Well-targeted, with negligible issues 
5     Perfectly targeted, no issues found 
 
A.  Engagement mean score =    
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SECTION B 
 
Functionality – app functioning, easy to learn, 
navigation, flow logic, and gestural design of app 
 
6.    Performance:  How accurately/fast do the app features 
(functions) and components 
(buttons/menus) work? 
 
1     App is broken; no/insufficient/inaccurate response (e.g. 
crashes/bugs/broken features, etc.) 
2     Some functions work, but lagging or contains major technical 
problems 
3     App works overall. Some technical problems need fixing/Slow at 
times 
4     Mostly functional with minor/negligible problems 
5     Perfect/timely response; no technical bugs found/contains a ‘loading 
time left’ indicator  
 
7.  Ease of use: How easy is it to learn how to use the app; how clear are 
the menu labels/icons and instructions? 
1     No/limited instructions; menu labels/icons are confusing; 
complicated 
2     Useable after a lot of time/effort 
3     Useable after some time/effort 
4     Easy to learn how to use the app (or has clear instructions) 
5     Able to use app immediately; intuitive; simple  
 
8.  Navigation: Is moving between screens 
logical/accurate/appropriate/ uninterrupted; are all necessary 
screen links present? 
1 Different sections within the app seem logically disconnected and 
random/confusing/navigation is difficult 
2     Usable after a lot of time/effort 
3     Usable after some time/effort 
4     Easy to use or missing a negligible link 
5     Perfectly logical, easy, clear and intuitive screen flow throughout, or 
offers shortcuts  
 
9.  Gestural design: Are interactions (taps/swipes/pinches/scrolls) 
consistent and intuitive across all components/screens? 
1     Completely inconsistent/confusing 
2     Often inconsistent/confusing 
3     OK with some inconsistencies/confusing elements 
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4     Mostly consistent/intuitive with negligible problems 
5     Perfectly consistent and intuitive  
 
B. Functionality mean score =     
 
 
 
 
SECTION C 
 
Aesthetics – graphic design, overall visual appeal, color scheme, and 
stylistic consistency 
 
10.  Layout: Is arrangement and size of buttons/icons/menus/content 
on the screen appropriate or zoom able if needed? 
1 Very bad design, cluttered, some options impossible to 
select/locate/see/read device display not optimized 
2     Bad design, random, unclear, some options difficult to 
select/locate/see/read 
3 Satisfactory, few problems with selecting/locating/seeing/reading 
items or with minor screen- size problems 
4     Mostly clear, able to select/locate/see/read items 
5 Professional, simple, clear, orderly, logically organized, device 
display optimized. Every design component has a purpose
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11.  Graphics: How high is the quality/resolution of graphics used for 
buttons/icons/menus/content? 
 
1 Graphics appear amateur, very poor visual design - 
disproportionate, completely stylistically inconsistent 
2 Low quality/low resolution graphics; low quality visual design – 
disproportionate, stylistically inconsistent 
3     Moderate quality graphics and visual design (generally consistent in 
style) 
4     High quality/resolution graphics and visual design – mostly 
proportionate, stylistically consistent 
5 Very high quality/resolution graphics and visual design - 
proportionate, stylistically consistent throughout 
 
12.  Visual appeal: How good does the app look? 
 
1     No visual appeal, unpleasant to look at, poorly designed, 
clashing/mismatched colors 
2     Little visual appeal – poorly designed, bad use of color, visually 
boring 
3     Some visual appeal – average, neither pleasant, nor unpleasant 
4     High level of visual appeal – seamless graphics – consistent and 
professionally designed 
5     As above + very attractive, memorable, stands out; use of color 
enhances app features/menus 
 
C. Aesthetics mean score =      
 
 
SECTION D 
 
Information – Contains high quality information (e.g. text, feedback, 
measures, references) 
from a credible source. Select N/A if the app component is irrelevant. 
 
13.  Accuracy of app description (in app store): Does app 
contain what is described? 
 
1     Misleading. App does not contain the described 
components/functions. Or has no description 
2     Inaccurate. App contains very few of the described 
components/functions 
3     OK. App contains some of the described components/functions 
4     Accurate. App contains most of the described components/functions 
5     Highly accurate description of the app components/functions  
 
14.  Goals: Does app have specific, measurable and achievable 
goals (specified in app store description or within the app 
itself)? 
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N/A Description does not list goals, or app goals are irrelevant to 
research goal (e.g. using a game for educational purposes) 
1     App has no chance of achieving its stated goals 
2     Description lists some goals, but app has very little chance of 
achieving them 
3     OK. App has clear goals, which may be achievable. 
4     App has clearly specified goals, which are measurable and 
achievable 
5     App has specific and measurable goals, which are highly likely to be 
achieved  
 
15.  Quality of information: Is app content correct, well written, and 
relevant to Sickle Cell disease ? 
N/A There is no information within the app 
1     Irrelevant/inappropriate/incoherent/incorrect 
2     Poor. Barely relevant/appropriate/coherent/may be incorrect 
3     Moderately relevant/appropriate/coherent/and appears correct 
4     Relevant/appropriate/coherent/correct 
5     Highly relevant, appropriate, coherent, and correct
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16.  Quantity of information: Is the amount of information in the App 
complete? 
N/A There is no information within the app 
1     Minimal or overwhelming 
2     Insufficient or possibly overwhelming 
3     OK but not comprehensive or concise 
4 Offers a broad range of information, has some gaps or 
unnecessary detail; or has no links to more information and 
resources 
5     Comprehensive and concise; contains links to more information and 
resources  
 
17.  Visual information: Can you understand the images displayed within 
the App? 
 
 
N/A There is no visual information within the app (e.g. it only contains 
audio, or text) 
1     Completely unclear/confusing/wrong or necessary but missing 
2     Mostly unclear/confusing/wrong 
3     OK but often unclear/confusing/wrong 
4     Mostly clear/logical/correct with negligible issues 
5     Perfectly clear/logical/correct  
 
 
D. Information mean score =                             * 
 
* Exclude questions rated as “N/A” from the mean score calculation.
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App subjective quality  
 
SECTION E 
 
 
20.  Would you recommend this app to people with sickle cell disease?  
1 Not at all I would not recommend this app to 
 2  There are very few people I would 
    3 Maybe There are several people whom I would 
   4  There are many people I would 
    5 Definitel
 
I would recommend this app to everyone 
 
21.  How many times do you think you would use this app in the next 12 
months if it was relevant to you? 
1     None 
2     1-2 
3     3-10 
4     10-50 
5     >50 
 
 
22.  Would you pay for this app? 
 
1     No 
3     Maybe 
5     Yes 
 
 
 
 
 
 
 
 
    
23.  What is your overall star 
rating of the app? 
 
1                                                               One of the worst apps I’ve used 
2      
3                                                Average 
4      
5                                  One of the best apps I've used
 
Scoring 
 
 
App quality scores for 
 
SECTION 
 
A: Engagement Mean Score =    
 
B: Functionality Mean Score =    
 
C: Aesthetics    Mean Score =     
 
D: Information Mean Score =     
 
App quality mean Score     =     
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App subjective quality Score =   
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App-specific 
 
These added items can be adjusted and used to assess the perceived impact of the app on the 
user’s knowledge, attitudes, intentions to change as well as the likelihood of actual change in the 
target health behavior. 
 
SECTION F 
 
1.     Awareness: This app is likely to increase awareness of the importance of 
addressing Sickle Cell disease 
 
Strongly 
 
   Strongly 
 1 2 3 4 5  
 
2.     Knowledge: This app is likely to increase knowledge/understanding of Sickle 
cell disease  
 
Strongly 
 
   Strongly 
 1 2 3 4 5 
 
3.     Attitudes: This app is likely to change attitudes toward improving Sickle cell 
disease 
 
Strongly 
 
   Strongly 
 1 2 3 4 5 
 
4.     Intention to change: This app is likely to increase intentions/motivation to 
address Sickle cell disease 
 
Strongly 
 
   Strongly 
 1 2 3 4 5 
 
5.     Help seeking: Use of this app is likely to encourage further help seeking for 
sickle cell disease 
 
Strongly 
 
   Strongly 
 1 2 3 4 5 
 
6.     Behavior change: Use of this app is likely increase/decrease sickle cell 
disease 
 
Strongly 
 
   Strongly 
 1 2 3 4 5 
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Appendix 4: IRB Approval Letter  
 
TO: Thokozeni Lipato  
CC: 
Catherine Law 
Thokozeni Lipato 
Wally Smith 
Daniel Sop 
 
  
 
FROM: VCU IRB Panel A  
RE: Thokozeni Lipato ; IRB HM20005141  Enhancing Adherence to Prescribed Opioids Using A Mobile-Based App: A Pilot Study in Non-Cancer Pain 
On 2/16/2017, the referenced research study was approved by expedited review according to 45 CFR 46.110 
by VCU IRB Panel A. This study is approved under Expedited categories 1, 7. 
The information found in the electronic version of this study’s smart form and uploaded documents now 
represents the currently approved study, documents, informed consent process, and HIPAA pathway (if 
applicable). You may access this information by clicking the Study Number above. 
This approval expires on 1/31/2018. Federal Regulations/VCU Policy and Procedures require continuing 
review prior to continuation of approval past that date. Continuing Review notices will be sent to you prior to 
the scheduled review. 
If you have any questions, please contact the Office of Research Subjects Protection (ORSP) or the IRB 
reviewer(s) assigned to this study. 
The reviewer(s) assigned to your study will be listed in the History tab and on the study workspace. Click on 
their name to see their contact information. 
Attachment – Conditions of Approval  
 
Conditions of Approval: 
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In order to comply with federal regulations, industry standards, and the terms of this approval, the 
investigator must (as applicable): 
1. Conduct the research as described in and required by the Protocol. 
2. Obtain informed consent from all subjects without coercion or undue influence, and provide 
the potential subject sufficient opportunity to consider whether or not to participate (unless 
Waiver of Consent is specifically approved or research is exempt). 
3. Document informed consent using only the most recently dated consent form bearing the 
VCU IRB “APPROVED” stamp (unless Waiver of Consent is specifically approved). 
4. Provide non-English speaking patients with a translation of the approved Consent Form in 
the research participant's first language.  The Panel must approve the translated version. 
5. Obtain prior approval from VCU IRB before implementing any changes whatsoever in the 
approved protocol or consent form, unless such changes are necessary to protect the safety 
of human research participants (e.g., permanent/temporary change of PI, addition of 
performance/collaborative sites, request to include newly incarcerated participants or 
participants that are wards of the state, addition/deletion of participant groups, etc.).  Any 
departure from these approved documents must be reported to the VCU IRB immediately as 
an Unanticipated Problem (see #7). 
6. Monitor all problems (anticipated and unanticipated) associated with risk to research 
participants or others. 
7. Report Unanticipated Problems (UPs), including protocol deviations, following the VCU IRB 
requirements and timelines detailed in VCU IRB WPP VII-6:  
8. Obtain prior approval from the VCU IRB before use of any advertisement or other material 
for recruitment of research participants. 
9. Promptly report and/or respond to all inquiries by the VCU IRB concerning the conduct of 
the approved research when so requested. 
10. All protocols that administer acute medical treatment to human research participants must 
have an emergency preparedness plan.  Please refer to VCU guidance on 
http://www.research.vcu.edu/human_research/guidance.htm. 
11. The VCU IRBs operate under the regulatory authorities as described within: 
a. U.S. Department of Health and Human Services Title 45 CFR 46, Subparts A, B, C, and 
D (for all research, regardless of source of funding) and related guidance documents. 
b. U.S. Food and Drug Administration Chapter I of Title 21 CFR 50 and 56 (for FDA 
regulated research only) and related guidance documents. 
c. Commonwealth of Virginia Code of Virginia 32.1 Chapter 5.1 Human Research (for all 
research). 
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